scholarly journals Malignant Lymphoma in the Parasellar Region

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Takao Koiso ◽  
Hiroyoshi Akutsu ◽  
Shingo Takano ◽  
Tetsuya Yamamoto ◽  
Eiichi Ishikawa ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Interleukin 2 ◽  
Elevated Serum ◽  
Compression Fracture ◽  
Bone Marrow Aspiration ◽  
B Cell Lymphoma ◽  
Good Prognosis ◽  
Mass Lesion ◽  
Pituitary Lymphoma ◽  
Systemic Lymphoma

The entity of pituitary (sellar or parasellar) lymphoma includes primary pituitary lymphoma (PPL) and secondary pituitary lymphoma (SPL). The latter has an involvement of systemic lymphoma. Both of these lymphomas are extremely rare. We describe a patient with SPL showing a good prognosis. A 78-year-old woman presented with diplopia, left ptosis, and back pain. Magnetic resonance (MR) imaging revealed a parasellar mass lesion extending to the upper clivus and another mass lesion with compression fracture of the Th3 vertebral body. Transsphenoidal exploration was performed, and it showed diffuse large B-cell lymphoma. Based on the positive tumor cells in the following bone marrow aspiration and hepatosplenomegaly in computed tomography (CT) findings, this patient was diagnosed as having a pituitary involvement of systemic lymphoma. After chemotherapy, she achieved complete remission for 4 years. The entity of pituitary lymphoma is extremely rare. Nineteen cases of PPL and 16 cases of SPL have been reported. Generally, clinical and radiological diagnosis was difficult because there are no specific findings. Therefore, biopsy was necessary in all of the cases. T2 hypointensity of a lesion in MR imaging in addition to an elevated serum level of soluble interleukin-2 receptor (sIL-2R) in a patient with a sellar lesion can be useful clues for the differential diagnosis of this rare disease.

Diffusion-weighted MR Imaging of Bone Marrow in the Spine: Differentiations of Metastatic Compression Fracture,Benign Compression Fracture,

2000 ◽  
Vol 43 (3) ◽  
pp. 349
Author(s):  
Byung Hak Rho ◽  
Woo Mok Byun ◽  
Won Gyu Park ◽  
Sang Ho An ◽  
Kil Ho Cho ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Mr Imaging ◽  
Compression Fracture ◽  
Diffusion Weighted

Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer

1994 ◽  
Vol 47 (3) ◽  
pp. 320-321
Author(s):  
A. Gadducci ◽  
M. Ferdeghini ◽  
G. Malagnino ◽  
C. Prontera ◽  
A. Fanucchi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Interleukin 2 ◽  
Elevated Serum ◽  
Serum Levels ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin’s lymphoma

1991 ◽  
pp. 43-47
Author(s):  
Angela Gause ◽  
Volker Roschansky ◽  
Astrid Tschiersch ◽  
Kleri Smith ◽  
Dirk Hasenclever ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Interleukin 2 ◽  
Good Prognosis ◽  
Hodgkin's Lymphoma ◽  
Interleukin 2 Receptor ◽  
Low Serum

scholarly journals Interim Serum Soluble Interleukin-2 Receptor Levels Are Strongly Associated with Prognosis in Newly Diagnosis DLBCL Patients

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4118-4118
Author(s):  
Haruya Okamoto ◽  
Akihiro Miyashita ◽  
Hiroaki Nagata ◽  
Yasuhiko Tsutsumi ◽  
Yuri Kamitsuji ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Interleukin 2 ◽  
B Cell Lymphoma ◽  
Clinical Variable ◽  
Rank Test ◽  
Prognostic Impact ◽  
Interleukin 2 Receptor ◽  
Log Rank Test ◽  
Soluble Interleukin 2 Receptor

<Background> Serum soluble interleukin-2 receptor (sIL2R) levels are often measured to evaluate the state of lymphoma. The serum sIL2R level at diagnosis has been reported to be correlated with the prognosis of diffuse large B cell lymphoma (DLBCL) patients treated with the R-CHOP regimen. However, it is unclear whether interim sIL2R levels are associated with prognosis in DLBCL. Here, we analyzed the prognostic impact of interim serum sIL2R levels in DLBCL. <Patients and Methods> We retrospectively examined data for DLBCL patients who started receiving chemotherapy at the Japanese Red Cross Society Kyoto Daini Hospital between January 2012 and December 2018. All of the patients received R-CHOP-like regimens (rituximab plus pirarubicin or adriamycin, cyclophosphamide, vincristine, and prednisolone). The interim sIL2R level (I-IL2R) was defined as the value measured after the third chemotherapy cycle. I-IL2R levels of >700 U/ml were regarded as positive. The primary endpoints of this study were progression-free survival (PFS) and overall survival (OS). The unadjusted probabilities of PFS and OS were estimated using the Kaplan-Meier method. The log-rank test and multivariate Cox regression analysis were used to assess the prognostic value of each clinical variable. <Results> In total, 102 patients were enrolled. The patients' median age was 73.5 years (range, 35-88), 58 patients (56.9%) were male, and 52 (51.0%) had poor revised International Prognostic Index scores. The median follow-up time was 25.2 months (range, 3.7-88.6). Twenty-three patients (22.5%) were I-IL2R-positive (>700 U/ml). Univariate analysis revealed that I-IL2R-positivity was associated with a poor prognosis. The 3-y PFS rates of the I-IL2R-negative (<700 U/ml) and I- IL2R-positive (>700 U/ml) patients were 60.4% (95% confidence interval [95%CI], 46.2-71.9) and 37.5% (95%CI, 15.7-59.4; p<0.001, log-rank test), respectively, and their 3-y OS rates were 82.2% (95%CI, 69.7-89.9) and 37.4% (95%CI, 13.8-61.4; p<0.001, log-rank test), respectively. Multivariate analysis confirmed that the I-IL2R level is independently associated with prognosis. <Conclusion> The I-IL2R level of >700 U/ml patients had poor prognosis. The I-IL2R level can be used to predict the outcomes of DLBCL patients. IL2R levels should be measured during chemotherapy, and I-IL2R-positive patients could be targeted with high-dose or novel therapies. As this study was based on a retrospective analysis and involved a small cohort and a limited follow-up period, further studies are needed to confirm the prognostic impact of I-IL2R. Figure Disclosures No relevant conflicts of interest to declare.

Central nervous system involvement in patients with diffuse large B cell lymphoma: analysis of the risk factors and prognostic from a single-center retrospective cohort study

2019 ◽  
Author(s):  
Jingjing Ma ◽  
Qing Li ◽  
Jie Shao ◽  
Yan Ma ◽  
Zhiguang Lin ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
Elevated Serum ◽  
B Cell Lymphoma ◽  
Cns Lymphoma ◽  
Absolute Count ◽  
Cns Involvement ◽  
Systemic Involvement ◽  
Large B Cell Lymphoma ◽  
Significant Difference ◽  
Deep Lesion

Abstract Purpose The aim of this study was to identify the risk factors for central nervous system (CNS) involvement in systemic diffuse large B-cell lymphoma (DLBCL) patients and to explore prognostic for DLBCL patients with CNS involvement (relapse or progression). Method This was a retrospective cohort study in our hospital. Data were collected from all DLBCL patients diagnosed in our institutes from January, 2013 to June, 2018. Clinical information was collected from medical records. Result The participants included 138 patients with DLBCL. Among them, 38 patients were diagnosed as CNS lymphoma, including 15 patients exhibited CNS involvement while DLBCL were pathologically confirmed, and 23 patients developed CNS lymphoma during or after initial chemotherapy. The median disease-free interval to CNS involvement was 13 months. Multivariate analysis identified elevated serum lactate dehydrogenase(LDH) level [hazard ratio(HR)=4.035; 95% confidence interval(95%CI):1.147~14.195] was independent predictor of CNS involvement. The median progression-free survival (PFS) and overall survival (OS) time of DLBCL patients with CNS involved were 12.5 months and 22 months, respectively. Multivariate prognostic analysis showed that eastern cooperative oncology group (ECOG) score>2(P=0.018; HR=7.333; 95%CI:1.424~42.002), elevated serum LDH level (P=0.046; HR=6.510; 95%CI:1.035~40.949), deep lesion (P=0.005; HR=10.957; 95%CI:2.050~58.569), and CNS with systemic involvement (P=0.023; HR=2.730; 95%CI:1.151~6.479) were independent poor prognostic factors for the patients. The cases with lymphocyte absolute count >0.75×109/L (HR=0.047; 95%CI:0.003~0.732) had better prognosis. The OS of DLBCL patients with secondary CNS lymphoma was inferior to DLBCL patients without CNS involvement. There was no significant difference between the patients with CNS and extra-CNS involvement. There was no significant difference between the patients with CNS involvement and stage III-IV DLBCL cases without CNS lymphoma. Conclusion In conclusion, elevated serum LDH was independent high-risk factor for secondary CNS lymphoma. For patients DLBCL with CNS involvement, ECOG score>2, elevated serum LDH level, deep lesion, lymphocyte absolute count ≤0.75×109/L and CNS with systemic involvement retained a significant association with outcome.

scholarly journals MR Imaging of a Methotrexate-associated Diffuse Large B-cell Lymphoma in the Liver that Regressed without Treatment

2016 ◽  
Vol 15 (3) ◽  
pp. 249-250
Author(s):  
Shota MORIKAWA ◽  
Ayako MORITA ◽  
Ritsuko FUJIMITSU ◽  
Yoshifumi KUROKI ◽  
Hiroshi URAKAWA ◽  
...  
Keyword(s):  
Mr Imaging ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Pancreatico-mediastinal fistula with a mediastinal mass lesion demonstrated by MR imaging

2002 ◽  
Vol 16 (6) ◽  
pp. 746-750 ◽  
Author(s):  
Mehmet Ö. Öksüz ◽  
Carsten Altehoefer ◽  
Jan T. Winterer ◽  
Marisa Windfuhr-Blum ◽  
Manuela Kleinschmidt ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Mediastinal Mass ◽  
Mass Lesion

Elevated Serum Soluble CD30 Precedes the Development of AIDS-Associated Non-Hodgkin’s B Cell Lymphoma

Tumor Biology ◽  
2006 ◽  
Vol 27 (4) ◽  
pp. 187-194 ◽  
Author(s):  
Elizabeth Crabb Breen ◽  
Sepi Fatahi ◽  
Marta Epeldegui ◽  
W. John Boscardin ◽  
Roger Detels ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Elevated Serum ◽  
B Cell Lymphoma ◽  
Soluble Cd30
Sign in / Sign up

Export Citation Format

Share Document